What is the current size and annual growth rate of the histone deacetylase (hdac) inhibitors market?
The histone deacetylase (HDAC) inhibitors market size has grown strongly in recent years. It will grow from $1.23 billion in 2024 to $1.33 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to a rise in funding for epigenetic research, rising prevalence of drug-resistant cancers, rise in healthcare expenditure, increasing utilization of HDAC inhibitors in veterinary medicine, and increasing investment in bioinformatics.
The histone deacetylase (HDAC) inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.77 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to the rising incidence of neurodegenerative disorders, growing awareness about cancer, rising investment in drug development, growing number of clinical trials, and increasing adoption of personalized medicine. Major trends in the forecast period include technological advancements, personalized medicine, cancer immunotherapy synergies, integration of digital health solutions, and bioinformatics.
Get Your Free Sample of The Global Histone Deacetylase (HDAC) Inhibitors Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18386&type=smp
What key drivers have fueled the histone deacetylase (hdac) inhibitors market’s development over the years?
The rising incidence of neurodegenerative disorders is expected to propel the growth of the histone deacetylase (HDAC) inhibitors market going forward. Neurodegenerative disorders, characterized by the progressive degeneration and death of neurons in the brain and spinal cord, lead to cognitive and motor dysfunction and include diseases such as Alzheimer’s, marked by memory loss and cognitive decline due to amyloid plaques and tau tangles. The rising incidence of neurodegenerative disorders can be attributed to several factors, such as age, longevity, genetics, and environmental factors. Histone deacetylase (HDAC) inhibitors are being explored as potential treatments for neurodegenerative disorders due to their ability to modulate gene expression and provide neuroprotective effects. For instance, in August 2024, according to the Centers for Disease Control and Prevention, a US-based federal agency, in the United States, an estimated 6.7 million older adults are currently living with Alzheimer’s disease, a number that is expected to rise to nearly 14 million by 2060. Therefore, the rising incidence of neurodegenerative disorders is driving the growth of the histone deacetylase (HDAC) inhibitors market.
What is the segmentation for the histone deacetylase (hdac) inhibitors market?
The histone deacetylase (HDAC) inhibitors market covered in this report is segmented –
1) By Class: Class I HDACs, Class II HDACs, Class III HDACs, Class IV HDACs
2) By Route Of Administration: Oral HDAC Inhibitors, Parenteral HDAC Inhibitors
3) By Application: Oncology, Neurology, Other Applications
4) By End User: Hospitals, Academic And Research Institutes, Pharmaceutical Companies, Other End Users
Subsegments
1) By Class I HDACs: HDAC1, HDAC2, HDAC3, HDAC8
2) By Class II HDACs: HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10
3) By Class III HDACs (Sirtuins): SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7
4) By Class IV HDACs: HDAC11
Order your report now for swift delivery
Who are the most influential companies in the histone deacetylase (hdac) inhibitors market?
Major companies operating in the histone deacetylase (HDAC) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.
What are the top industry trends projected to impact the histone deacetylase (hdac) inhibitors market?
Major companies operating in the histone deacetylase (HDAC) inhibitors market are focused on developing innovative solutions, such as HDAC inhibitors for cancer treatment, to enhance efficacy and reduce side effects. Histone deacetylase (HDAC) inhibitors are a class of pharmaceutical compounds used in cancer treatment. They function by inhibiting the activity of HDAC enzymes, which generally remove acetyl groups from histone proteins. This inhibition leads to increased acetylation of histones, altering chromatin structure and influencing gene expression. For instance, in September 2023, Shuttle Pharmaceuticals Holdings Inc., a US-based company that develops first-in-class therapies for cancer, was awarded New HDAC Inhibitor Patents for Cancer Treatment by the U.S. Patent and Trademark Office. These innovative inhibitors are tailored to target specific HDAC enzymes implicated in cancer progression, aiming to disrupt aberrant gene expression patterns that contribute to tumor growth and metastasis. The patented compounds demonstrate enhanced potency and selectivity, minimizing off-target effects and improving safety profiles for patients undergoing treatment.
What are the major regional insights for the histone deacetylase (hdac) inhibitors market, and which region holds the top position?
North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (HDAC) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Histone Deacetylase (HDAC) Inhibitors Market Report 2025 Offer?
The histone deacetylase (hdac) inhibitors market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Histone deacetylase (HDAC) inhibitors refer to a class of compounds that block the activity of histone deacetylase enzymes. These enzymes are responsible for removing acetyl groups from histone proteins, which leads to a more condensed chromatin structure and reduced gene expression. HDAC inhibitors can promote hyperacetylation of histones, which generally leads to a more relaxed chromatin structure and increased accessibility of DNA for transcription factors.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18386
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
